Hepatitis and liver disease Flashcards
Hep A
Acute
fecal-oral
vaccine yes
1st tx is supportive
Hep B
acute and chronic
blood, body fluid
vaccine yes
1st tx- PEG-INF or NRT (tenofovir or entacavir)
Hep C
acute and chronic
blood, body fluid
vaccine no
1st tx- treatment-naive: DAA combo
other: DAA combo + RBV or/w PEG-INF
Interferon
not recommended but could play a role DAA to expensive
ritonavir
not active for HCV, generally used as a boost to PI
NS3/4A
Protease Inhibitors
-previr
P for PI
ex: glecaprevir, grazoprevir, paritaprevir, voxilaprevir
NS5A
Replication Complex Inhibitors
-asvir
A for NS5A
ex: elbasvir, ledipasvir, ombitasvir, pibrentasvir, velpatasvir
NS5B
Polymerase inhibitors
-buvir
B for NS5B
ex: dasabuvir, sofosbuvir
PIG
protease inhibitor & Grub
Take With Food
except Zepatier- w/o regard to food, fosamprenavir oral suspension w/o food
All DAAs
- risk of reactivation HBV, test all pt for HBV before starting
- sofsobuvir- regimens do not use amiodarone! serious bradycardia
Glecaprevir/pibrentasvir
Mavyret
w/food
- contra in child-pugh B or C
- do not use with efavirenz or HIV protease inhibitors (atazanavir, darunavir, lopinavir, ritonavir), or Ethinyl estradiol contain products
Sofosbuvir/velpatasvir
epclusa
protect from moister
savaldi, epclusa, harvoni, vosevi
because it contains sofosbuvir that needs to be protected from most. these are combo drugs with sofosbuvir
pan-genotypic
approved for all 6 HCV geno types for patient- naive pts.
Epclusa and Mavyret
8 week course for select pts
Mavyret
salvage therapy (in failed previous therapy)
Vosevi and Mayvret (select pts)
sofosbuvir/velpatasvir/voxilaprevir
Vosevi
sofosbuvir
sovaldi
monotherapy not effective
DAA Drug interaction
-contra for strong cyp inducers… carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, st. johns worst.
Sofosburvir/ledipasvir
Harvoni
Harvoni, Epclusa and Vosevi
DI
antacids, H2RAs, and PPI, can decrease concentration
- antacids separate by 4 hrs
- PPI not recommended with Epclusa